Clinical Trials

1,188 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT05593094 2026-02-25

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

210 enrolled

CNS

Brain Neoplasms

NCT05081609 2026-02-24

IL Believe

Phase 1/2 Active not recruiting

320 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04158258 2026-02-12

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active not recruiting

2,907 enrolled

Breast Neoplasms

NCT05415215 2026-02-10

ProHer

346 enrolled 20 charts

Phase 2 Active not recruiting

Breast Neoplasms, Patient Preference, Inflammatory Breast Neoplasms

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

720 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03975647 2025-12-10

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

466 enrolled 17 charts

HER2-positive Breast Cancer

NCT03529110 2025-10-21

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

524 enrolled 11 charts 1 FDA

Breast Neoplasms

NCT05945927 2025-10-10

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

Completed

178 enrolled

Breast Neoplasms

NCT07008976 2025-08-14

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

Phase 3 Recruiting

246 enrolled

Breast Neoplasms

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT01772472 2025-07-22

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

1,486 enrolled 37 charts 1 FDA

Phase 1 Active not recruiting

Breast Neoplasms

NCT05650879 2025-07-15

HER2

198 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04622319 2025-05-09

DESTINY-Breast05

1,600 enrolled

HER2-Positive Primary Breast Cancer

NCT06126640 2025-05-02

A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

Phase 3 Recruiting

1,600 enrolled

HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy

NCT04509596 2025-04-01

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

23 enrolled

Breast Cancer Metastatic

NCT06846437 2025-03-24

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Phase 3 Recruiting

228 enrolled

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT01120184 2024-03-04

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

1,095 enrolled 46 charts

Breast Neoplasms

NCT05755048 2023-09-01

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 3 Unknown

314 enrolled

Breast Neoplasms

NCT03084939 2023-05-06

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

351 enrolled

Breast Neoplasms

NCT01702571 2022-04-04

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

2,185 enrolled 20 charts

Breast Neoplasms

NCT04298918 2021-11-08

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Terminated

1 enrolled

Breast Neoplasms

NCT02658734 2021-04-02

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Phase 4 Completed

70 enrolled 18 charts

Breast Neoplasms

NCT02924883 2021-02-17

KATE2

202 enrolled 21 charts

Breast Neoplasms

NCT01983501 2020-09-21

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

57 enrolled

Breast Neoplasms

NCT02605915 2020-02-05

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

98 enrolled

Breast Neoplasms

NCT02999672 2019-08-28

KAMELEON

GastrointestinalGenitourinary

20 enrolled 14 charts

Urinary Bladder Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT02289833 2019-08-07

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

49 enrolled 22 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00833963 2019-05-16

MotHER

Completed

20 enrolled

Breast Neoplasms

NCT03153163 2018-11-23

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

11 enrolled

Breast Neoplasms

NCT01641939 2017-05-12

A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Phase 2/3 Terminated

415 enrolled 25 charts

Gastrointestinal

Stomach Neoplasms

NCT00934856 2017-04-06

A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer

Phase 1/2 Completed

98 enrolled 40 charts

Breast Neoplasms

NCT00679211 2017-03-31

A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

110 enrolled 12 charts

Breast Neoplasms

NCT02144012 2017-03-07

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer

Phase 3 Terminated

49 enrolled 16 charts

Breast Neoplasms

NCT01120561 2017-02-15

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

No longer available

Breast Neoplasms

NCT00928330 2016-11-02

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

57 enrolled

Breast Neoplasms

NCT01513083 2016-11-02

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

28 enrolled

Breast Neoplasms

NCT00829166 2016-10-31

EMILIA

991 enrolled 26 charts

Breast Neoplasms

NCT01419197 2016-10-12

TH3RESA

602 enrolled 15 charts

Breast Neoplasms

NCT00951665 2016-06-24

A Study of Trastuzumab Emtansine, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer

Phase 1/2 Completed

107 enrolled 31 charts

Breast Neoplasms

NCT00932373 2015-08-26

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

54 enrolled 25 charts

Breast Neoplasms

NCT00991562 2014-11-21

IMGN901 in Combination With Lenalidomide and Dexamethasone

50 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT01196052 2014-10-06

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

153 enrolled 11 charts

Breast Neoplasms

NCT00679341 2014-01-09

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

137 enrolled 13 charts

Breast Neoplasms

NCT00875979 2013-12-24

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Phase 1/2 Completed

67 enrolled 9 charts

Breast Neoplasms

NCT00943670 2013-05-27

Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

51 enrolled 27 charts